Article,

Wild-type and mutated IDH1/2 enzymes and therapy responses

, , , and .
Oncogene, 37 (15): 1949--1960 (2018)
DOI: 10.1038/s41388-017-0077-z

Abstract

Isocitrate dehydrogenase 1 and 2 (IDH1/2) are key enzymes in cellular metabolism, epigenetic regulation, redox states, and DNA repair. IDH1/2 mutations are causal in the development and/or progression of various types of cancer due to supraphysiological production of d-2-hydroxyglutarate. In various tumor types, IDH1/2-mutated cancers predict for improved responses to treatment with irradiation or chemotherapy. The present review discusses the molecular basis of the sensitivity of IDH1/2-mutated cancers with respect to the function of mutated IDH1/2 in cellular processes and their interactions with novel IDH1/2-mutant inhibitors. Finally, lessons learned from IDH1/2 mutations for future clinical applications in IDH1/2 wild-type cancers are discussed.

Tags

Users

  • @marcsaric

Comments and Reviewsshow / hide

  • @marcsaric
    5 years ago (last updated 5 years ago)
Please log in to take part in the discussion (add own reviews or comments).